Everything you need to know about Darktrace
When is the Darktrace IPO?
Darktrace made its market debut on the London Stock Exchange on April 30 at 250p a share. The transaction gave the company a valuation of £1.7 billion.
Shortly after 8am GMT, the company's shares rose to more than 358p, representing a 43% boost from its original IPO price.
While Darktrace had lowered its pricing for the float from a rumoured £3 billion valuation, the company is expected by some analysts to successfully ride the wave of anticipation surrounding fast-growth tech stocks. The London listing will be closely watched following the disappointing Deliveroo IPO in March.
Read about more IPOs set for 2021.
How much is Darktrace worth?
Darktrace is worth £1.7 billion based on its IPO on April 30 2021.
As of 2018 Darktrace was valued at $1.65 billion following a $50 million Series E funding round. The company’s Series D round amounted to $75 million in 2017, which valued the company at $825 million. Before that, Darktrace also raised $64 million in 2016, and $23 million in 2015.
How to trade Darktrace shares
Darktrace shares are available to trade with City Index following its April IPO.
You can start trading shares in just a few quick steps:
- Open a City Index account, or log in if you’re already a customer
- Search for Darktrace in our award-winning platform
- Choose your position and size, and your stop and limit levels
- Place the trade
What is Darktrace?
Darktrace is an artificial intelligence (AI) company with a focus on cybersecurity. It develops solutions for organisations to detect emerging online threats, using technology based on machine learning and AI algorithms to prepare clients for potential attacks.
The company works by installing an appliance in a client’s network infrastructure. The device employs its machine learning capabilities to detect suspicious activity, using Bayesian mathematical equations to assess the probability of an attack, and neutralises threats before they turn into crises.
Darktrace’s products include Darktrace Industrial, Darktrace Enterprise, Darktrace Cloud and Darktrace SaaS, all software applications designed to target threats from various online sources.
Headquartered in Cambridge, the company has more than 1,500 employees across 44 offices globally, and saw revenues of more than £100 million for its latest accounts filed in 2019.
How does Darktrace make money?
Darktrace makes money through cybersecurity contracts with corporations, governments and banks, reportedly charging clients based on the number of IP addresses or networked devices managed.
This can result in a contract being worth anything from a few thousand to several hundred thousand pounds per month.
The company has counted Micron, Rolls-Royce, Coca-Cola, Siemens, and NHS trusts as some of its key customers.
Is Darktrace profitable?
As of its latest 2019 accounts, Darktrace is not a profitable business, having racked up losses of £21.8 million on revenues of some £100 million. However, these losses were trimmed from £27.6 million the prior year.
Founder Poppy Gustafsson said in 2018 that the profitability of the business was being put on hold as the company’s high-growth phase placed hiring and international expansion as an immediate priority.
Who are Darktrace’s competitors?
Darktrace’s competitors include IT multinationals such as Cisco, which offers its own b2b cyber defence solutions, as well as specialist cybersecurity companies such as Fortinet, Palo Alto Networks, FireEye and ESET. Additionally, there are a host of other companies releasing new products in response to the constantly-evolving cybersecurity marketplace.
While Darktrace’s revenues are currently dwarfed by many of the American cybersecurity giants in a hugely competitive sector, the company is widely considered to be a major early adopter and leading innovator specifically of AI-based cybersecurity solutions. Today, however, as more and more companies enter the AI space, Darktrace may find tougher barriers to scale than previously encountered.
What is Darktrace’s strategy?
From its launch in 2013, Darktrace set out to ‘fundamentally transform the ability of organisations to defend their most critical assets in the face of rising cyber threat’. On launch, the company’s technology was widely regarded as pioneering in its design to enable network infrastructures to mirror the human immune system in dealing with threats.
The strategy evolved over the years to incorporate Autonomous Response technology, which allowed the ‘immune system’ to react to in-progress cyberattacks with a higher degree of precision. 2019 saw the release of the Cyber AI Analyst, which further strengthened a company’s ability to defend attacks through automation of the threat investigation and reporting process.
Who are the directors of Darktrace?
Darktrace was founded in 2013 by Poppy Gustafsson, Jack Stockdale, Dave Palmer, Emily Orton, and Nicole Eagan. In addition to the core founders, there are a number of prominent board members and advisors, including Robert Webb QC, former General Counsel of Rolls Royce and British Airways, and Alan Wade, former CIO of the CIA.
Here are some of the key personnel at the company:
- CEO and Director: Poppy Gustafsson
- Chief Financial Officer: Cathy Graham
- Chief Technology Officer: Jack Stockdale
- Chief Technology Officer, Americas: Eloy Avila
- Chief Marketing Officer: Emily Orton
- Chief Information Security Officer: JR Tietsort
StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.
No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.
For further details see our full non-independent research disclaimer and quarterly summary.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. CFD and Forex Trading are leveraged products and your capital is at risk. They may not be suitable for everyone. Please ensure you fully understand the risks involved by reading our full risk warning.
City Index is a trading name of StoneX Financial Ltd. Head and Registered Office: 1st Floor, Moor House, 120 London Wall, London, EC2Y 5ET. StoneX Financial Ltd is a company registered in England and Wales, number: 05616586. Authorised and regulated by the Financial Conduct Authority. FCA Register Number: 446717.
City Index is a trademark of StoneX Financial Ltd.
The information on this website is not targeted at the general public of any particular country. It is not intended for distribution to residents in any country where such distribution or use would contravene any local law or regulatory requirement.
© City Index 2024